The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation

• Status: Unknown status
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Recently a new category of antihyperglycemic therapy aiming to modulate the incretin system has emerged. These drugs induce insulin secretion without inducing hypoglycemia. The effect of the incretin modulators drugs on hypertension, arterial stiffness, inflammation and oxidative stress parameters have not been fully investigated yet.GLP-1 analogue has been suggested to have an effect on endothelium and the development of hypertension. Nystrom et al have demonstrated that GLP-1 improves endothelial dysfunction in a small group of type 2 diabetes subjects, with coronary heart disease. We hypothesize that DPP-4 inhibitor will have an effect on hypertension and arterial stiffness by effect on the NO pathway.The aim of this study is to investigate the effect of two insulin inducers drugs, sulfonyl urea and DPP-4 inhibitor on 24 hours blood pressure monitoring, arterial stiffness, oxidative stress and inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assaf-Harofeh Medical Center
• Treatments: Glyburide; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• diabetic patients

• aged 18 years or older

• treated with metformin

• Only patients with HbA1C levels within the range 7% - 11% will be enrolled in the study

Exclusion Criteria:

• CCT<30

• A history of treatment with incretins or sulfonylurea during the last 3 months

• Treatment with nitrates

• Uncontrolled heart failure

• Uncontrolled hypertension and/or any change in the hypertensive medications within one month prior starting the study

• No proven regular treatment with aspirin or statins within one month prior starting the study

• Any malignancy with life expectancy of less then 1 year

• pregnancy